Camurus AB
CAMRF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.67B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $3.67 Billion |
|---|---|
| Enterprise Value | $-191,093,888.00 |
| Earnings per Share | $12.42 |
| Beta | 0.52 |
| Outstanding Shares | 59,509,184 |
Return
| Return on Equity | 14.49% |
|---|---|
| Return on Assets | 12.78% |
| Return on Invested Capital | 17.82% |
Valuation & Multiples
| P/E Ratio | 58.47 |
|---|---|
| PEG | -3615.43 |
| Price to Sales | 1.63 |
| Price to Book Ratio | 0.79 |
| Enterprise Value to Revenue | 15.81 |
| Enterprise Value to EBIT | 41.77 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Last Earnings Call
Report Date
July 15, 2026
EPS Estimate
$0.33
Consensus analyst estimateRevenue Estimate
$64.48 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.37
Consensus analyst estimateRevenue Estimate
$70.09 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Camurus AB
285 employees
CEO: Sven Fredrik Tiberg
Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, whic...